Biotechnology
Commented by Nico Popp on June 22nd, 2022 | 12:32 CEST
Market-independent returns? This is how it's done! Valneva, NervGen, BioNTech
When the stock market is in high gear, it is time for cool heads. Even if many managers are suspected of only having an eye on the next few quarters, there are still some decisions with far-reaching consequences, especially in the case of takeovers and mergers. Most recently, Pfizer acquired a stake in the vaccine manufacturer Valneva. The share price performance to date did not suggest such a step. Here is why the decision could still pay off for shareholders and what signal effect the deal will have.
Read
Commented by Armin Schulz on June 17th, 2022 | 10:45 CEST
BioNTech, Defence Therapeutics, Formycon - Biotech stocks with a lot of future potential
A look at the NASDAQ Biotechnology Index shows that the big hype on biotech companies seems to be over for now. Since September 2021, the index has been falling, repeatedly marking new lows. However, this decline can also be seen as an opportunity because the long-term prospects for the industry are good. People are getting older, and with age comes the diseases that want to be fought. Today we look at three companies with a lot of potential for the future.
Read
Commented by Stefan Feulner on June 16th, 2022 | 11:01 CEST
Biotech stocks ahead of the turnaround - Evotec, NervGen and MorphoSys
Biotechnology stocks could not escape the current correction. The broad-based NASDAQ Biotechnology Index, for example, has lost around 40% since its peak last August. The fact that biotechnology will increasingly become a key technology in the future was already demonstrated during the Corona pandemic when tests, vaccines and drugs were developed in a very short time and made available in large quantities. Thus, more and more capital is likely to move into the sector in the coming years, with great opportunities for the individual companies.
Read
Commented by Nico Popp on June 14th, 2022 | 12:26 CEST
Unheeded crisis signals! What is next: BioNTech, Lufthansa, Triumph Gold
There are always comeback stocks on the stock market. The airports are full of travellers who are being drawn to distant countries. So the tourism industry, and airlines too, could almost strap themselves in for a comeback. If only it weren't for the new BA.5 virus variant, which has infected large parts of the population in Portugal within a very short time. It seems investors have to choose between travel stocks and pandemic stocks when looking for comeback stocks - or is there a laughing third party?
Read
Commented by Armin Schulz on June 10th, 2022 | 11:48 CEST
BioNTech, NervGen Pharma, Valneva - Which stock will make the breakthrough in incurable diseases?
The number of cancer patients increases every year, and only if the disease is detected at an early stage might a cure still be possible. With other diseases such as multiple sclerosis or Alzheimer's, there is no chance of a cure at all. The deterioration progresses slowly and unstoppably. COVID-19 has also shown us how vulnerable humanity is to a virus. But many biotech companies have taken up the fight against these diseases. Any drug that can stop the progression of these diseases would help those affected. Many biotech stocks have corrected significantly recently. Today we take a look at three companies and their existing potential against incurable diseases.
Read
Commented by Juliane Zielonka on June 9th, 2022 | 12:25 CEST
wallstreet:online, Alibaba, Novavax - Digital pioneers and old hands
The number of young investors in Germany is rising steadily. To date, it stands at 49,000 people who are actively involved in their retirement planning. Both private and institutional investors are discovering the field of neobrokers as an investment. wallstreet:online AG is a candidate from the field with its own community. Alibaba founder Jack Ma has recognized that money has to keep moving in order to flow and is launching the first digital bank in Singapore. Things are somewhat more leisurely in the pharmaceutical sector: with Novavax, Americans now have four vaccines to choose from.
Read
Commented by Carsten Mainitz on June 8th, 2022 | 11:35 CEST
Valneva, Defence Therapeutics, Bayer - Blockbusters: Turbos for your share portfolio!
Blockbusters are drugs with which companies generate sales of more than USD 1 billion per year. Corona vaccines are currently an integral part of the global hit list. But also many application areas in different cancer fields or cardiovascular diseases offer a large market worth billions. Like BioNTech, a company with the right pipeline and the resulting compounds can quickly evolve from a start-up into an established and profitable player.
Read
Commented by Carsten Mainitz on June 7th, 2022 | 11:32 CEST
XPhyto, BioNTech, MorphoSys - The next price wave is coming!
In recent years, Corona has been the most urgent topic that has moved the world and the stock markets. Health care is and remains a megatrend. It is in the nature of things that the focus changes over time. Innovative approaches or forms of drug delivery, on the other hand, remain perennial favorites. There is also a lot of progress in research against cancer. These companies will play a major role in the future.
Read
Commented by Stefan Feulner on June 1st, 2022 | 14:03 CEST
After the slump in biotech stocks - Bavarian Nordic, XPhyto and Evotec under review
Biotechnology experienced a boom in March 2020, when the world realized what biotech innovations could do to fight COVID-19. Investors pounced on the many promising technologies, driving up the stock prices of vaccine producers and making it easier for companies to raise capital for financing. However, since September of last year, the biotech sector has been on a steep downhill slide, at least on the stock market. The NASDAQ Biotechnology Index has lost more than 30% of its value since its high of 5,449.26 points until today. This drastic decline is reminiscent of the bursting of the bubble in the year 2000. But where are the opportunities now, and which stocks should investors rather refrain from investing in?
Read
Commented by Fabian Lorenz on June 1st, 2022 | 13:44 CEST
Rain of money for BioNTech shareholders: What are Nordex and Meta Materials doing?
BioNTech shareholders are in for a windfall. A dividend of EUR 2 per share is to be approved at today's Annual General Meeting. Also on the agenda is a share buyback program with a volume of up to USD 1.5 billion. In addition, analysts at Goldman Sachs have commented positively on the German biotech champion. Meta Materials shareholders are still a long way from a dividend. But the hot stock has announced exciting details about its fight against stroke. At Nordex, by contrast, supply chain problems, plant closures and cyberattacks dominate the headlines. But analysts see the light at the end of the tunnel - and rightly so?
Read